These data indicate that the anti-CD26 antibody does not exhibit substantial cytotoxic effects on CRC cells at therapeutically relevant concentrations, supporting its potential safety for further therapeutic investigations. The gene discussed is DPP4; the disease is colorectal carcinoma.